Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study
- PMID: 9547669
- DOI: 10.1023/a:1005993705237
Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study
Abstract
Background: Chemotherapy resistance is probably multifactorial; hence, we assessed the feasibility of adding to carboplatin 6 concurrent resistance modulators in 53 patients with resistant cancers.
Methods: Pentoxifylline and dipyridamole were added to carboplatin 400 mg/m2 in cohort 1, and metronidazole was also given in cohort 2. Mannitol and saline were administered in each cohort with the theoretical objective of improving carboplatin delivery to tumors by reducing blood viscosity. Because of excessive toxicity in cohort 2, cohort 3 received the same modulators as in cohort 2 but with a reduced dose of carboplatin (200 mg/m2). Subsequent patients had the following drugs added to those in the previous cohort: novobiocin (cohort 4), tamoxifen (cohort 5), ketoconazole (cohort 6). Cohort 7 patients received the 6 cohort 6 modulators along with carboplatin 300 mg/m2.
Results: Thrombocytopenia was excessive in early cohorts with a carboplatin dose of 400 mg/m2, but was minimal at lower doses. Other toxicity was generally tolerable and reversible, particularly at carboplatin doses < or = 300 mg/m2, although gastrointestinal and neurological toxicity tended to worsen as additional modulators were added. No major responses (but 4 minor responses) were seen in this patient population with heavily pretreated or primarily resistant cancers.
Conclusions: Acceptable doses for phase II studies are carboplatin 300 mg/m2, 20% mannitol 250 ml plus normal saline 500 ml over 1 hr prior to carboplatin, pentoxifylline 700 mg/m2/day p.o. from 3 days before carboplatin to cessation of therapy, dipyridamole 100 mg/m2 p.o. q6h x 6 days starting 24 hr before carboplatin, metronidazole (750 mg/m2 p.o. 12 hr and immediately before, and 24 hr after carboplatin; 250 mg/m2 suppository p.r. 12 hr and immediately before, and 6 and 24 hr after carboplatin; and 500 mg/m2 i.v. right after carboplatin), novobiocin 600 mg/m2 p.o. q12h x 6 days starting 24 hr before carboplatin, and tamoxifen 100 mg/m2/day plus ketoconazole 700 mg/m2/day x 3 days starting the day before carboplatin, with oral dexamethasone and ondansetron as antimetics.
Similar articles
-
Concurrent use of multiple chemotherapy resistance modulators with etoposide in patients with resistant malignancies.Int J Oncol. 1997 Oct;11(4):709-16. doi: 10.3892/ijo.11.4.709. Int J Oncol. 1997. PMID: 21528265
-
Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.Cancer Chemother Pharmacol. 1997;41(1):1-8. doi: 10.1007/s002800050700. Cancer Chemother Pharmacol. 1997. PMID: 9443607
-
Phase I-II trial of concomitant continuous carboplatin (CBDCA) infusion and radiotherapy in advanced nonsmall cell lung cancer with evaluation for surgery: final report.Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):93-101. doi: 10.1016/s0360-3016(96)00471-3. Int J Radiat Oncol Biol Phys. 1997. PMID: 9054882 Clinical Trial.
-
Combined carboplatin and cisplatin. Limited prospects for dose intensification.Cancer. 1993 Jun 15;71(12):4060-6. doi: 10.1002/1097-0142(19930615)71:12<4060::aid-cncr2820711242>3.0.co;2-0. Cancer. 1993. PMID: 8508371 Review.
-
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.Oncology (Williston Park). 2003 May;17(5 Suppl 5):36-40. Oncology (Williston Park). 2003. PMID: 12800605 Review.
Cited by
-
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.Crit Rev Oncol Hematol. 2010 Sep;75(3):173-234. doi: 10.1016/j.critrevonc.2009.11.006. Epub 2010 Jan 4. Crit Rev Oncol Hematol. 2010. PMID: 20047843 Free PMC article. Review.
-
A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.Invest New Drugs. 2012 Oct;30(5):1887-98. doi: 10.1007/s10637-011-9752-z. Epub 2011 Oct 8. Invest New Drugs. 2012. PMID: 21983700
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources